New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry

Journal of Pathology

Volumn 183, Issue 2, 1997, Pages 228-232

  Bevitt, Debra J ^a   Milton, Ian D ^a   Piggot, Nigel ^a   Henry, Linda ^a   Carter, Michael J ^b   Toms, Geoffrey L ^b   Lennard, Tom W J ^b   Westley, Bruce ^b   Angus, Brian ^b,c   Horne, Charles H W ^b  

^a Novocastra Laboratories Ltd   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Breast cancer; Monoclonal antibodies; Oestrogen receptor; Paraffin embedded tissue; Progesterone receptor

Indexed keywords

ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; PARAFFIN; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR DENSITY; TISSUE SECTION;

ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; PARAFFIN EMBEDDING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0030801367     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199710)183:2<228::AID-PATH895>3.0.CO;2-X     Document Type: Article

References (41)

1. Hawkins RA, Roberts MM, Forrest APM. Oestrogen receptors and breast cancer: current status. Br J Surg 1980; 67: 153-169.
2. Scottish Cancer Trials Breast Group and ICRF Breast Unit GH London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 1993; 341: 1293-1298.
3. Maudelonde T, Khalaf S, Garcia M. et al. Immunoenzymatic assay of Mr 52,000 cathepsin D in 182 breast cancer cytosols: low correlation with other prognostic parameters. Cancer Res 1988; 48: 462-466.
4. Henry JA, McCarthy AL, Angus B, et al. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer 1990; 65: 265-271.
5. Tetu B, Brisson J, Cote C, Brisson S, Potvin D, Roberge N. Prognostic significance of cathepsin-D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer 1993; 55: 429-435.
6. Luqmani YA, Ricketts D, Ryall G, Turnbull L, Law M, Coombes RC. Prediction of response to endocrine therapy in breast cancer using immunocytochemical assays for pS2, oestrogen receptor and progesterone receptor. Int J Cancer 1993; 54: 619-622.
7. Henry JA, Piggott NH, Mallick UK, et al. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer 1991; 63: 615-622.
8. Hurlimann J, Gebhard S, Gomez F. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 1993; 23: 239-248.
9. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor J Biol Chem 1978; 252: 2223-2228.
10. Clark GM, McGuire WL. The clinical usefulness of oestrogen-receptor and other markers of hormone dependence. Proc R Soc Edinburgh 1989; 95B: 145-150.
11. Henry JA, Angus B, Horne CHW. Oestrogen receptor and oestrogen regulated proteins in human breast cancer: a review. Keio J Med 1989; 38: 241.
12. Rayter Z. Steroid receptors in breast cancer. Br J Surg 1991; 78: 528-535.
13. Howell A, Barnes DM, Harland RNL, et al. Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet 1984; 1: 588-591.
14. Williams MR, Todd JH, Ellis IO, et al. Estrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Br J Cancer 1987; 55: 67-73.
15. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treatment 1992; 22: 207-219.
16. Barnes DM, Millis RR, Fentiman IS, Rubens RD. Who needs steroid receptor assays? Lancet 1989; 1: 1126-1127.
17. Mason BH, Holdaway IM, Mullins PR, Yee LH, Kay RG. Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 1983; 43: 2985-2990.
18. Chevallier B, Heintzmann F, Mosseri V, et al. Prognostic value of estrogen and progesterone receptors in operable breast cancer. Results of a univariate and multivariate analysis. Cancer 1988; 62: 2517-2524.
19. Clark GM, McGuire WI, Hubay CA, Pearson OH, Marshall JS. Progesterone receptors as a prognostic factor in stage II breast cancer. N Engl J Med 1983; 309: 1343-1347.
20. Thorpe SM, Rose C, Rasmussen BB, et al. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res 1987; 47: 6126-6133.
21. Hawkins RA, Sangster K, Krajewski A. Histochemical detection of oestrogen receptors in breast carcinoma: a successful technique. Br J Cancer 1986; 53: 407-410.
22. Giri DD, Dangerfield VJM, Lonsdale R, Rogers K, Underwood JCE. Immunohistology of oestrogen receptor and D5 antigen: correlations with radioligand binding assays and enzyme immunoassays. J Clin Pathol 1987; 40: 734-740.
23. Thorpe SM. Monoclonal antibody technique for detection of oestrogen receptors in human breast cancer: greater sensitivity and more accurate classification of receptor status than the dextran-coated charcoal method. Cancer Res 1987; 47: 6572-6575.
24. Soomro S, Shousha S. Demonstration of progesterone receptors in paraffin wax sections of breast carcinoma. J Clin Pathol 1990; 43: 671-674.
25. Snead DRJ, Bell JA, Dixon AR, et al. Methodology of immunohisto-logical detection of oestrogen receptor in human breast carcinoma in formalin-fixed, paraffin-embedded tissue: a comparison with frozen section methodology. Histopathology 1993; 13: 233-238.
26. Raymound WA, Leong AS-Y. Oestrogen receptor staining of paraffin-embedded breast carcrnomas following short fixation in formalin: a comparison with cytosolic and frozen section receptor analyses. J Pathol 1990; 160: 295-303.
27. Chang C-D, Meienhofer J. Solid-phase peptide synthesis using mild base cleavage of N-fluorenylmethyloxycarbonyl amino acids, exemplified by a synthesis of dihydrosomatostatin. In J Peptide Protein Res 1978; 11: 246-249.
28. Liu F-T, Zinnecker M, Hamaoka T, Katz DH. New procedures for preparation and isolation of conjugates of proteins and a synthetic copolymer of D-amino acids and immunochemical characterization of such conjugates. Biochemistry 1979; 18: 690-697.
29. Green N, Alexander H, Olsen A, et al. Immunogenic structure of the influenza virus hemagglutinin. Cell 1982; 28: 477-487.
30. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning; A Laboratory Manual. 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989: 7.19-7.22.
31. Cuevas EC, Bateman AC, Wilkins BS, et al. Microwave antigen retrieval in immunocytochemistry: a study of 80 antibodies. J Clin Pathol 1994; 47: 448-452.
32. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin fixed paraffin embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991; 39: 741-748.
33. AlSaati T, Clamens S, Cohen-Knafo E, et al. Production of monoclonal antibodies to human estrogen-receptor protein (ER) using recombinant ER (RER). Int J Cancer 1993; 55: 651-654.
34. Saccani Jotti G, Johnston SRD, Salter J, et al. Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay. J Clin Pathol 1994; 47: 900-905.
35. Press MF, Udove JA, Greene GL. Progesterone receptor distribution in the human endometrium. Am J Pathol 1988; 131: 112-124.
36. Barnes DM, Millis RR. Progress in Pathology 2. Edinburgh: Churchill Livingstone, 1995; 89-114.
37. Al-Tamimi S, Cowan WK, Horne CHW, Angus B. Are interval cancers detected in breast screening programmes biologically distinct from those presenting clinically: an immunohistochemical study. Manuscript in preparation.
38. Forrest APM, Hawkins RA, Anderson EDC, Chetty U, Stewart HJ. Who needs steroid receptor assays? Lancet 1989; 2: 40.
39. Early Breast Cancer Trialists' Collaborative Group. Systemic treatmenl of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15, 71-85.
40. Pertshuk LP, Feldman JG, Kim YD, et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp7 in frozen sections or cytosol based ligand binding assays. Cancer 1996; 77: 2514-2518.
41. Detre S, Saccani Joui G, Dowsett M. A 'quickscore' method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995; 48: 876-878.